180 related articles for article (PubMed ID: 35741048)
1. T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.
Pulvirenti F; Di Cecca S; Sinibaldi M; Piano Mortari E; Terreri S; Albano C; Guercio M; Sculco E; Milito C; Ferrari S; Locatelli F; Quintarelli C; Carsetti R; Quinti I
Cells; 2022 Jun; 11(12):. PubMed ID: 35741048
[TBL] [Abstract][Full Text] [Related]
2. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
[TBL] [Abstract][Full Text] [Related]
3. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
[TBL] [Abstract][Full Text] [Related]
5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
6. Antigen-Specific CD4
Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
Front Immunol; 2022; 13():827048. PubMed ID: 35237272
[TBL] [Abstract][Full Text] [Related]
7. Elevated CD21
Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
[TBL] [Abstract][Full Text] [Related]
8. Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.
Barmettler S; DiGiacomo DV; Yang NJ; Lam T; Naranbhai V; Dighe AS; Burke KE; Blumenthal KG; Ling M; Hesterberg PE; Saff RR; MacLean J; Ofoman O; Berrios C; St Denis KJ; Lam EC; Gregory D; Iafrate AJ; Poznansky M; Lee H; Balazs A; Pillai S; Farmer JR
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1622-1634.e4. PubMed ID: 35381395
[TBL] [Abstract][Full Text] [Related]
9. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
Front Immunol; 2022; 13():907125. PubMed ID: 35784359
[TBL] [Abstract][Full Text] [Related]
10. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
11. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
Quinti I; Locatelli F; Carsetti R
Front Immunol; 2021; 12():815404. PubMed ID: 35126372
[TBL] [Abstract][Full Text] [Related]
12. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
[TBL] [Abstract][Full Text] [Related]
13. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
Shin JJ; Par-Young J; Unlu S; McNamara A; Park HJ; Shin MS; Gee RJ; Doyle H; Afinogenova Y; Zidan E; Kwah J; Russo A; Mamula M; Hsu FI; Catanzaro J; Racke M; Bucala R; Wilen C; Kang I
J Clin Immunol; 2022 Aug; 42(6):1137-1150. PubMed ID: 35713752
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS.
Pulvirenti F; Mortari EP; Putotto C; Terreri S; Fernandez Salinas A; Cinicola BL; Cimini E; Di Napoli G; Sculco E; Milito C; Versacci P; Agrati C; Marino B; Carsetti R; Quinti I
J Allergy Clin Immunol Pract; 2023 Jan; 11(1):292-305.e2. PubMed ID: 36280136
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
[TBL] [Abstract][Full Text] [Related]
16. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
17. A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection.
Laranjeira P; Rodrigues T; Silva A; Barbosa P; Reis T; Lopes C; Pinho A; Silva S; Silva I; Carvalho A; Pacheco V; Rodrigues F; Araújo L; Antunes I; Paiva A
Clin Exp Med; 2023 Jun; 23(2):529-537. PubMed ID: 35190936
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
19. Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity.
Silva-Moraes V; Souquette A; Sautto GA; Paciello I; Antonelli G; Andreano E; Rappuoli R; Teixeira-Carvalho A; Ross TM
Immunohorizons; 2023 Oct; 7(10):635-651. PubMed ID: 37819998
[TBL] [Abstract][Full Text] [Related]
20. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
